Loading WSTNR…
WSTNR • CIK 0002076192
Overview. We are a Cayman Islands company incorporated on June 3, 2025, as an exempted company with limited liability. We chose to incorporate in the Cayman Islands due to (i) its tax-neutrality, which allows international transactions to be structured efficiently without an additional layer of tax and (ii) simplicity of establishment and flexibility of administration, including easy migration to another jurisdiction, the existence of statutory procedures for merger or consolidation, and no takeover code or bespoke public company filing requirements. We were formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities, which we refer to as a “target business.” Subsequent to June 30, 2026, on July 22,2026, we entered into a Business Combination Agreement (the “Business Combination Agreement”) with First Choice Healthcare Solutions, Inc., a Delaware Corporation (“First Choice”) and First Choice Acquisition Corp., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”), as disclosed in our Current Report on Form 8-K filed on July 29, 2026. Our efforts to identify a prospective target business will not be limited to a particular industry or geographic location. While we intended to conduct a global search for target businesses without being limited by geographic region, our executive officers have experience investing in and building businesses in the Asia Pacific region and have a deep understanding of the region’s business environment, regulations, regulatory bodies and culture. We will not undertake our initial business combination with any company being based in or having the majority of the company’s operations in Greater China (which includes, solely for purposes of this Annual Report, the People’s Republic of China, Hong Kong, Taiwan and Macau). Following the execution of the Business Combination Agreement described above, we are no longer pursuing other prospective target businesses and are focused on completing the proposed Business Combination. We may retain all of our available funds and any future earnings following a business combination to fund the development and growth of our business. As a result, we may not expect to pay any cash dividends in the foreseeable future. We believe our management team is well positioned to identify and evaluate attractive business combination opportunities and to execute transactions that have the potential to create value for our shareholders. Our management team has extensive experience in cross-border mergers and acquisitions, capital raising, deal-making and investment, and has developed relationships with industry executives, private owners, private equity funds, family offices, commercial and investment bankers, lawyers and other financial sector service providers and participants. Initial Public Offering and Private Placement In June 2025, the Company issued an aggregate of 2,012,500 Class B ordinary shares, per value $0.0001 per share (the “Initial Shares”), to the Sponsor for an aggregate consideration of $25,000, or approximately $0.0124 per share. Of the 2,012,500 Initial Shares issued and outstanding, up to 262,500 Initial Shares were subject to forfeiture to the extent that the underwriters’ over-allotment option was not exercised. On November 5, 2025, the underwriters fully exercised the over-allotment option, and as a result, the 262,500 Initial Shares were no longer subject to forfeiture. The Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of our initial business combination, or earlier at the option of the holders thereof on a one-for-one basis, subject to the adjustments described in our Registration Statement. On November 5, 2025, the Company consummated its initial public offering (the “IPO”) of 5,750,000 units (the “Units”), which included 750,000 Units issued pursuant to the full exercise of the underwriters’ over-allotment option. Each Unit consists of one Class A ordinary share, par value $0.0001 per share, of the Company (the “Ordinary Shares”) and one right to receive one-sixth (1/6) of one Class A ordinary share upon the consummation of the Company’s initial business combination.…